Simin Kovacs, DO in Dickinson, ND - Pathology

Simin Kovacs, DO is a Pathology - Clinical Pathology/laboratory Medicine physician based in Dickinson, North Dakota. Simin Kovacs is licensed to practice in North Dakota (license number 7235) and her current practice location is 30 7th St W, Dickinson, North Dakota. She can be reached at her office (for appointments etc.) via phone at (701) 456-4000.

NPI number for Simin Kovacs is 1659394948 and her current mailing address is 30 7th St W, Dickinson, North Dakota. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1659394948.

Contact Information

	Simin Kovacs, DO
	30 7th St W, Dickinson, ND 58601-4335
	(701) 456-4000
	Not Available

Physician's Profile

Full Name	Simin Kovacs
Gender	Female
Speciality	Pathology - Clinical Pathology/laboratory Medicine
Location	30 7th St W, Dickinson, North Dakota
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1659394948
Provider Enumeration Date: 07/26/2006
Last Update Date: 02/01/2008

Medical Identifiers

Medical identifiers for Simin Kovacs such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1659394948	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207ZP0105X	Pathology - Clinical Pathology/laboratory Medicine	7235 (North Dakota)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Simin Kovacs is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Simin Kovacs, DO 30 7th St W, Dickinson, ND 58601-4335 Ph: (701) 456-4000	Simin Kovacs, DO 30 7th St W, Dickinson, ND 58601-4335 Ph: (701) 456-4000

News Archive

Protein deficiency in Down syndrome patients could contribute to cognitive impairment and congenital heart defects

Conventional wisdom among scientists for years has suggested that because individuals with Down syndrome have an extra chromosome, the disorder most likely results from the presence of too many genes or proteins contained in that additional structure.

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California.

Mucosal lining of the female genital tract no barrier to HIV sexual transmission

Contrary to a widely-held assumption about heterosexual transmission of HIV, the normal mucosal lining of the female genital tract is not a foolproof barrier to viral penetration, scientists at the Northwestern University School of Medicine in Chicago report at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

Hand washing tips to protect against many infections

As the beginning of the school year approaches, parents need to remind their children about the importance of hand washing. Every day people touch several surfaces including books, desks, door knobs, sink handles, and other people and many of them harbor germs like bacteria and viruses that can cause illnesses.

FDA accepts Horizon Pharma's DUEXA NDA for review

Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.

Simin Kovacs, DO - Pathology in Dickinson, ND